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Adaptation to new environments is of fun-damental importance in ecology. Infectious agents and cancer cells also relentlessly 
adapt to escape detection by the immune system 
and to avoid being killed by drugs targeted at 
them. The nature and extent of adaptive changes 
in various human pathogens have been studied 
under well-controlled conditions in the laboratory 
(Foll et al., 2014; Szamecz et al., 2014), and also 
in clinical samples (Mukherjee et al., 2011; Poon 
et al., 2012). Several mutations leading to drug 
resistance in Candida albicans, a species of yeast 
that causes oral and genital infections in humans, 
have been identified through targeted gene 
sequencing or large-scale genotyping approaches 
(MacCallum et al., 2010; Dhamgaye et al., 2012). 
Now, in eLife, Dawn Thompson and Aviv Regev 
of the Broad Institute of MIT and Harvard and co-
workers—including Christopher Ford and Jason 
Funt as joint first authors—describe the genomic 
adaptation of C. albicans when it is exposed to a 
common antifungal compound (Ford et al., 2015).
C. albicans is found in a large fraction of the 
human population. Normally, it does not affect 
its host, but it can become pathogenic in peo-
ple with weakened immune systems (Mayer 
et al., 2013). C. albicans has a diploid genome—
a common feature of sexually reproducing spe-
cies, featuring two sets of each chromosome—but 
has a predominantly asexual life cycle (Diogo et al., 
2009). These genetic features are very similar to 
those of cancer cells (Landau et al., 2013).
To shed light on the development of drug 
resistant strains in vivo, Ford, Funt et al. studied 
samples from HIV-infected individuals diagnosed 
with a fungal infection called oral candidiasis and 
treated with fluconazole. This drug works by pre-
venting C. albicans making a molecule called ergos-
terol that is incorporated into the cell membrane: 
without this molecule the yeast cell can't grow.
Ford, Funt et al. analyzed 43 fungal isolates 
collected from 11 individuals, with several sam-
ples taken from each individual over a period 
of several months. Using deep-sequencing tech-
nology, they obtained a whole genome sequence 
of C. albicans from each sample, which allowed 
them to produce a comprehensive catalogue of 
the different genetic variants of the fungus. These 
variants range from single nucleotide mutations 
in the DNA of the cells to large-scale genetic 
changes such as loss of heterozygosity (where one 
of the two copies of a chromosomal region is lost) 
and aneuploidies (where the cell contains either 
more or fewer chromosomes than normal). Of note, 
all sequencing data have been made publicly avail-
able, which is an unprecedented resource for the 
research community.
The first isolate, collected before treatment 
started, provided a snapshot of pre-existing 
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genetic variation and was used to filter out non-
drug-related mutations. To identify the genes 
that are under selection pressure during flucon-
azole therapy, Ford, Funt et al. searched for 
mutations called ‘non-synonymous coding sin-
gle nucleotide polymorphisms’ that emerged 
and persisted in at least three of the patients 
under treatment. These mutations alter a single 
DNA nucleotide, which subsequently changes 
the identity of an amino acid in one of the pro-
teins produced by the cell. Such mutations 
were observed in a total of 240 genes, notably 
including genes encoding proteins involved in 
fungal cell wall formation or in the regulation of 
the efflux pumps that move toxic substances out 
of the cell.
Among the larger-scale genetic variants, loss 
of heterozygosity events were significantly associ-
ated with higher drug resistance, whereas most 
aneuploidies were transient and had no detectable 
impact. However, aneuploidies may still indirectly 
help resistance to develop by increasing the like-
lihood that loss of heterozygosity events occur 
following the loss of a chromosome. Measurement 
of the in vitro fitness of the sequenced strains 
convincingly demonstrated that C. albicans had 
adapted to fluconazole: the measured fitness of 
the last isolate was indeed higher in the presence 
of the drug than without it.
Because a single colony was sequenced at 
each time point, it was not possible to distinguish 
between the appearance of new mutations and 
the selection of pre-existing minority variants in 
response to drug pressure. Most isolates from 
each individual were highly related, suggesting 
that samples collected in the same patient 
share the same common ancestor. Despite this 
clonal relationship, significant within-host diver-
sity was present, as various isolates of the same 
patient differed by thousands of single nucleo-
tide polymorphisms.
A remaining open question is whether pre-
existing genetic variation is maintained at low 
levels in the C. albicans population throughout the 
treatment period, or if only drug-selected strains 
are conserved. To address this, more in-depth 
genomic analyses of fungal sub-populations are 
needed. An obvious first step would be to study 
the loss of heterozygosity events in greater detail, 
because such mutations are irreversible in clonal 
populations with a purely asexual life cycle. 
Therefore, valuable insights into the diversity of 
C. albicans inside a single host could be gained 
by investigating whether any of the resistance-
inducing loss of heterozygosity events reverses 
after fluconazole treatment has ended.
The work by Ford, Funt et al. provides a global 
description of the genetic processes underlying 
drug resistance and adaptation in C. albicans. 
What else could now be learned about microbial 
evolution using deep sequencing technology? 
First, the analysis of multiple strains collected 
simultaneously in the same infected patient 
has the potential to reveal population structure, 
dynamics and diversity. Second, mechanistic and 
temporal details governing the emergence of 
escape mutations will certainly be gained from in 
vitro experiments, including the characterization 
of single colonies over time. Finally, the sequenc-
ing of paired host and pathogen genomes opens 
the door to innovative studies of host-specific 
adaptation.
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